{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T06:35:44.761234+00:00","company":{"ticker":"MIRM","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"ad5f19bfa9cc8415f707eec1fb64820890675a76","cik":1759425,"ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-05-18T20:06:05+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-15","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"0.00%","item_codes_triggered":["2.03"],"maturity_text":"June 1, 2032","principal_text":"$690.0 million aggregate principal amount"},"claim":"Mirum Pharmaceuticals, Inc. incurred convertible notes of $690.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.","evidence_excerpt":"On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-228902","anchor_url":"https://secwatch.observer/filing/0001193125-26-228902#claim-ad5f19bfa9cc8415f707eec1fb64820890675a76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm"},{"fact_type":"earnings_release","fact_key":"a0ccd53701ab7846bcac39a5b004b0e759410a59","cik":1759425,"ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$159.9 million"},"claim":"Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $159.9 million. Guidance raised.","evidence_excerpt":"in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update – Q1 2026 net product sales of $159.9 million – 2026 net product sales guidance increased to $660 to $680 million – Volixibat VISTAS Phase 2b study met primary endpoint – Brelovitug Phase 2b portion of AZURE-1 study met","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001759425-26-000036","anchor_url":"https://secwatch.observer/filing/0001759425-26-000036#claim-a0ccd53701ab7846bcac39a5b004b0e759410a59","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/0001759425-26-000036-index.htm"},{"fact_type":"ma_transaction","fact_key":"799661d3527c496b22f4041de76d5d22e4071644","cik":1759425,"ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-01-23","consideration_text":"up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock","counterparty":"Bluejay Therapeutics, Inc.","effective_date":"2026-01-23","item_codes_triggered":["2.01"]},"claim":"Mirum Pharmaceuticals, Inc. completed an acquisition involving Bluejay Therapeutics, Inc. for up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock (closed 2026-01-23).","evidence_excerpt":"of the Mergers, the Company acquired Target’s net cash of approximately $56.6 million and paid or will pay to the holders of Target’s securities up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock, subject to the Company’s receipt of deliverables that are a condition to payment and deduction to satisfy applicable","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-022582","anchor_url":"https://secwatch.observer/filing/0001193125-26-022582#claim-799661d3527c496b22f4041de76d5d22e4071644","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/0001193125-26-022582-index.htm"},{"fact_type":"earnings_release","fact_key":"9f70d48457ac8e279864b65cccfdd8bb149bfc46","cik":1759425,"ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$69.2 million"},"claim":"Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.","evidence_excerpt":"such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001759425-24-000017","anchor_url":"https://secwatch.observer/filing/0001759425-24-000017#claim-9f70d48457ac8e279864b65cccfdd8bb149bfc46","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm"},{"fact_type":"earnings_release","fact_key":"471c1afa0deaa9a1d3136ed2292cdf4829aa9ebe","cik":1759425,"ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-02-28","result_type":"reported_results","revenue_text":null},"claim":"Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).","evidence_excerpt":"On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001759425-24-000005","anchor_url":"https://secwatch.observer/filing/0001759425-24-000005#claim-471c1afa0deaa9a1d3136ed2292cdf4829aa9ebe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm"}]}